文献速递病毒性肝炎

识别需要抗病毒治疗的慢性乙型肝炎灰区患者模型:一项多中心回顾性研究

A Model to Identify Gray Zone Patients With Chronic Hepatitis B Requiring Antiviral Therapy: A Multicenter Retrospective Study.
PubMed 文献 · J Infect Dis · 2025-01-01

本研究回顾性收集2010至2023年6家医院200例经无创指标评估不需要抗病毒治疗的慢性乙型肝炎灰区患者,随机分为建模队列140例和验证队列60例,构建预测肝活检是否需要抗病毒治疗的列线图。78例(39%)经肝活检被判定需要抗病毒治疗,模型纳入年龄、丙氨酸氨基转移酶、淋巴细胞百分比、血小板计数和国际标准化比值,建模队列曲线下面积0.755、验证队列0.707。作者认为该模型是有前景的工具。

要点

  • 200例灰区患者中78例(39%)经肝活检判定需要抗病毒治疗。
  • 模型纳入年龄、丙氨酸氨基转移酶、淋巴细胞百分比、血小板计数和国际标准化比值。
  • 建模队列曲线下面积0.755,验证队列0.707。

核心结论

  • 作者认为,应当识别需要抗病毒治疗的灰区患者,本研究开发的模型是有前景的工具。

研究设计与样本

  • 多中心回顾性研究,2010至2023年在6家医院收集200例经无创指标评估不需要抗病毒治疗的慢性乙型肝炎灰区患者,随机分为建模队列140例和验证队列60例。
  • 采用单因素和多因素回归分析筛选自变量,构建列线图预测肝活检判定需要抗病毒治疗的概率。

主要发现

  • 78例(39%)患者被判定需要抗病毒治疗。
  • 年龄的OR为1.06(95%CI 1.01-1.11)。
  • 丙氨酸氨基转移酶的OR为2.43(95%CI 1.08-5.59)。
  • 淋巴细胞百分比的OR为6.43(95%CI 1.23-33.64)。
  • 血小板计数的OR为0.99(95%CI 0.98-1.00),国际标准化比值(每0.01)的OR为0.99(95%CI 0.98-1.00)。

关键数值与推荐

  • 模型在建模数据集的曲线下面积为0.755,在验证数据集的曲线下面积为0.707,并显示良好的校准度和临床适用性。
  • 临床试验注册号:ClinicalTrials.gov NCT06041022。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals who do not match any specific immune stage of chronic hepatitis B are classified into the gray zone, and appropriate management for these patients remains unclear. This study aimed to develop and validate a noninvasive model to identify gray zone patients requiring antiviral therapy (AVT). METHODS: We retrospectively collected data on 200 gray zone patients not requiring AVT, according to assessment by noninvasive parameters from 2010 to 2023 in 6 hospitals, and randomized them into development (n = 140) and validation (n = 60) cohorts. Univariable and multivariable regression analyses were performed to identify independent variables for establishing a nomogram to predict the probability of requiring AVT by liver biopsy. RESULTS: Seventy-eight patients (n = 39%) were identified as requiring AVT. The following were identified as independent variables for constructing the nomogram: age (odds ratio [OR], 1.06; 95% CI, 1.01-1.11), alanine aminotransferase (OR, 2.43; 95% CI, 1.08-5.59), lymphocyte percentage (OR, 6.43; 95% CI, 1.23-33.64), platelet count (OR, 0.99; 95% CI, .98-1.00), and international normalized ratio (per 0.01) (OR, 0.99; 95% CI, .98-.1.00). These variables showed good discriminability based on the development data set (area under the curve, 0.755) and validation data set (area under the curve, 0.707), calibration, and clinical applicability. CONCLUSIONS: Gray zone patients requiring AVT should be identified, and the model developed here is a promising tool. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT06041022.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yang XY, Li XD, Wu BY, et al. A Model to Identify Gray Zone Patients With Chronic Hepatitis B Requiring Antiviral Therapy: A Multicenter Retrospective Study. J Infect Dis. 2025. PMID: 39960318. doi:10.1093/infdis/jiaf070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。